Home » Stocks » Sophiris Bio

Sophiris Bio Inc. (SPHS)

Stock Price: $0.0100 USD -0.0012 (-10.71%)
Updated Aug 7, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 344,720
Revenue (ttm) n/a
Net Income (ttm) 37,000
Shares Out 32.00M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $0.0100
Previous Close $0.0112
Change ($) -0.0012
Change (%) -10.71%
Day's Open 0.3001
Day's Range 0.0100 - 0.0112
Day's Volume 55,883
52-Week Range 0.0035 - 1.0700

More Stats

Market Cap 344,720
Enterprise Value n/a
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 32.00M
Float n/a
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share -0.33
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.42M
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 16.02
Revenue n/a
Operating Income -10.17M
Net Income 37,000
Free Cash Flow -10.54M
Net Cash 465,000
Net Cash / Share 0.01
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC 16.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$3.75*
Low
3.75
Current: $0.0100
High
3.75
Target: 3.75
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20182017201620152014201320122011
Revenue-----5.00--
Gross Profit-----5.00--
Operating Income-15.14-11.92-10.31-13.49-30.04-9.79-19.21-13.30
Net Income-6.78-8.63-11.16-14.20-30.71-11.15-21.19-14.20
Shares Outstanding30.1230.1123.0016.8816.598.033.052.35
Earnings Per Share-0.23-0.29-0.49-0.84-1.85-1.39-6.94-6.05
Operating Cash Flow-13.46-9.97-10.33-14.36-26.23-13.21-18.84-12.34
Capital Expenditures-----0.01--0.03-0.25
Free Cash Flow-13.46-9.97-10.33-14.36-26.24-13.21-18.86-12.60
Cash & Equivalents12.5425.8429.008.3822.7048.159.7223.41
Total Debt7.016.81-5.345.946.8812.0214.70
Net Cash / Debt5.5319.0429.003.0416.7541.27-2.308.71
Assets13.2026.8830.008.8925.5951.8911.5324.80
Liabilities11.4619.2315.676.9910.9011.6116.6317.80
Book Value1.747.6514.321.9114.6940.28-5.117.00
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Sophiris Bio Inc.
Country United States
Employees 6
CEO Randall E. Woods

Stock Information

Ticker Symbol SPHS
Stock Exchange US OTC
Sector Health Technology
Industry Biotechnology
Unique Identifier OTCMKTS: SPHS

Description

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.